Oxygen Biotherapeutics, Inc. Outlines Plans for New Products During Investor Conference Presentation
13 Januar 2010 - 6:23PM
PR Newswire (US)
DURHAM, N.C., Jan. 13 /PRNewswire-FirstCall/ -- Oxygen
Biotherapeutics, Inc. (OTC:OXBT) (BULLETIN BOARD: OXBT) chairman
and CEO Chris Stern outlined plans for the introduction of new
products during a presentation today at the OneMedForum 2010
investor conference in San Francisco. During the brief
presentation, limited by conference organizers to 10 minutes per
company, Stern said Oxygen Biotherapeutics, Inc. plans to launch
four products in its cosmetics line during 2010. They include an
eye cream for fine line wrinkles around the eyes, a face lotion, an
improved oxygen concentrate gel, and a perfluorocarbon skin
oxygenating liquid -- all based on the company's perfluorocarbon
oxygenating technology. Stern also told the audience that the
company has developed and plans to add two veterinary product lines
based on Oxycyte(TM). Depending on regulatory approval, the first
line could launch this year. It will feature topical wound
treatment solutions. That would be followed by an intravenous
veterinary product for multiple indications. Oxycyte is the
Company's perfluorocarbon (PFC) therapeutic oxygen carrier. The
presentation was webcast live. A link to the replay will be posted
on the company website. About Oxygen Biotherapeutics, Inc. Oxygen
Biotherapeutics, Inc. is dedicated to commercializing innovative
pharmaceuticals and medical devices in the field of oxygen
therapeutics and Defense Medicine(TM). The company has developed a
perfluorocarbon (PFC) therapeutic oxygen carrier and liquid
ventilation product (Oxycyte(TM)) and has out-licensed an
implantable glucose sensor. These products are based upon core
technologies that include biomedical applications for PFCs as well
as medical and industrial applications for biosensors. Each of the
product candidates is designed with advantages over currently
marketed products in major markets including traumatic brain
injury, sickle cell crisis, trauma, wound care, decompression
sickness, acute respiratory distress syndrome, stroke, myocardial
infarction, surgery, diabetes wounds and ulcers, and cosmetic
applications which are being marketed under the Dermacyte name.
More information is available at http://www.oxybiomed.com/. Caution
Regarding Forward-Looking Statements This news release contains
certain forward-looking statements by Oxygen Biotherapeutics, Inc.
that involve risks and uncertainties and reflect the company's
judgment as of the date of this release. These statements include
those referring to plans to launch new products in the cosmetics
and veterinary markets and the timing for such product launches.
Actual events or results may differ from Oxygen Biotherapeutics,
Inc.'s expectations. There can be no assurance that the products
will reach the market in the estimated time period or at all.
Additional information concerning these and other risk factors
affecting Oxygen Biotherapeutics, Inc.'s business can be found in
the company's public periodic filings with the Securities and
Exchange Commission, which are available via
http://www.oxybiomed.com/. Oxygen Biotherapeutics, Inc. disclaims
any intent or obligation to update these forward-looking statements
beyond the date of this release. This caution is made under the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. DATASOURCE: Oxygen Biotherapeutics, Inc. CONTACT: Abe
Wischnia of Abe Wischnia & Associates, +1-619-795-2345, for
Oxygen Biotherapeutics, Inc. Web Site: http://www.oxybiomed.com/
Copyright